European Parliament Urges Increased Role For Generics And Biosimilars
Industry Welcomes Call For A ‘Greater Market Presence’ For Off-Patent Drugs
Executive Summary
A report adopted by the European Parliament calling for measures to support a “greater market presence for generic and biosimilar medicines” has been welcomed by Medicines for Europe.
You may also be interested in...
Access In Jeopardy If Generics Excluded From EU Centralized Procedure
Recent suggestions by the European Commission’s Pharmaceutical Committee that generics could be excluded from the centralized procedure for marketing authorizations would create barriers to access and put extra pressure on the European regulatory network overall, Medicines for Europe believes. The association has urged the authorities to abandon the idea.
Access In Jeopardy If Generics Excluded From EU Centralized Procedure
Recent suggestions by the European Commission’s Pharmaceutical Committee that generics could be excluded from the centralized procedure for marketing authorizations would create barriers to access and put extra pressure on the European regulatory network overall, Medicines for Europe believes. The association has urged the authorities to abandon the idea.
Biosimilars Saved European Countries €5.7bn Last Year, Says IQVIA Report
This year’s annual IQVIA report into European biosimilar competition has found savings in the market are at record highs, but Medicines for Europe says more action is needed to translate the potential of biosimilars into real-world changes.